Search
Tango Therapeutics Inc
TNGXAdd to Watchlist
28.560USD
+0.920+3.33%
Close 07/17, 16:00（ET）Quotes delayed by 15 min
4.64BMarket Cap
LossP/E TTM
More Details of Tango Therapeutics Inc Company
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Tango Therapeutics Inc Info
Ticker SymbolTNGX
Company nameTango Therapeutics Inc
IPO dateSep 03, 2020
CEOWeber (Barbara)
Number of employees155
Security typeOrdinary Share
Fiscal year-endSep 03
Address201 Brookline Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02215
Phone18573204900
Websitehttps://www.tangotx.com/
Ticker SymbolTNGX
IPO dateSep 03, 2020
CEOWeber (Barbara)
Company Executives of Tango Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
144.97K
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
131.69K
-0.93%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
15.25K
+26.23%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
-3111.11%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
--
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
10.25K
+39.02%
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
Mr. Kanishka Pothula
Mr. Kanishka Pothula
Independent Director
Independent Director
--
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
144.97K
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
131.69K
-0.93%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
15.25K
+26.23%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
-3111.11%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
--
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
10.25K
+39.02%
FAQs
Who are the top five shareholders of Tango Therapeutics Inc?
The top five shareholders of Tango Therapeutics Inc are: Dr. Adam S. Crystal, M.D., Ph.D.
How many institutions hold shares of Tango Therapeutics Inc (TNGX)?
As of 2026Q1, 357 institutions hold shares of Tango Therapeutics Inc, with a combined market value of approximately 177.88M, accounting for 123.32% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 35874415.00.